An international multicenter cohort study of 28,280 non-metastatic breast cancer patients described that better recurrence free survival and OS of HER2-low did not correlate with HER2 IHC score and mainly resulted from the HER2 IHC1+ subgroup [12]. Here, ERBB2 is linked to breast cancer.